

US011266785B2

(12) United States Patent

Simpson et al.

(54) MEDICAL CONNECTOR WITH INTERNAL VALVE MEMBER MOVABLE WITHIN MALE PROJECTION

- (71) Applicant: ICU Medical, Inc., San Clemente, CA (US)
- (72) Inventors: Philip J. Simpson, Escondido, CA
 (US); Walter D. Gillespie, San Diego, CA (US); David G. Matsuura, Encinitas, CA (US)
- (73) Assignee: ICU Medical, Inc., San Clemente, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 14 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 16/162,286
- (22) Filed: Oct. 16, 2018

(65) **Prior Publication Data**

US 2019/0046731 A1 Feb. 14, 2019

Related U.S. Application Data

- (63) Continuation of application No. 15/916,778, filed on Mar. 9, 2018, now Pat. No. 10,105,492, which is a (Continued)
- (51) Int. Cl. *A61M 5/31* (2006.01) *A61M 39/26* (2006.01)

(Continued)

(Continued)



(45) **Date of Patent:** *Mar. 8, 2022

(58) Field of Classification Search CPC A61M 39/10; A61M 39/22; A61M 39/26; A61M 2039/2473; A61M 2039/2486; (Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,254,997 A	9/1941	Fisher
2,456,045 A	12/1948	Brock
	(Con	tinued)

FOREIGN PATENT DOCUMENTS

CA	2747283 A1	7/2002
EP	0 158 030	10/1985
	(Cont	tinued)

OTHER PUBLICATIONS

- U.S. Appl. No. 14/020,579, filed Oct. 22, 2015, Fangrow et al.
- U.S. Appl. No. 15/499,740, filed Apr. 27, 2017, Fangrow.
- U.S. Appl. No. 15/789,242, filed Oct. 20, 2016, Fangrow. Jr. et ai. (Continued)

Primary Examiner — Kami A Bosworth

(74) Attorney, Agent, or Firm — Knobbe Martens Olson & Bear, LLP

(57) ABSTRACT

Disclosed herein is a valve assembly comprising a male luer end portion and a female luer end portion and a passage for the transfer of fluids extending between the male and female luer end portions, valve means movable between a first position, in which the passage is closed, and a second position, in which the passage is open, biasing means for biasing the valve means toward the first position, and actuating means extending into the male luer end portion and coupled to the valve means to actuate the valve means when a female luer end portion of a medical accessory is engaged with the male luer end portion.

18 Claims, 15 Drawing Sheets



Related U.S. Application Data

continuation of application No. 15/648,147, filed on Jul. 12, 2017, now Pat. No. 9,913,945, which is a continuation of application No. 14/052,592, filed on Oct. 11, 2013, now Pat. No. 9,707,346, which is a continuation of application No. 13/305,663, filed on Nov. 28, 2011, now Pat. No. 8,556,868, which is a continuation of application No. 12/789,255, filed on May 27, 2010, now Pat. No. 8,066,692, which is a continuation of application No. 10/584,920, filed as application No. PCT/US2004/042723 on Dec. 21, 2004, now Pat. No. 7,758,566.

- (60) Provisional application No. 60/532,916, filed on Dec. 30, 2003.
- (51) Int. Cl.

A61M 39/10	(2006.01
A61M 39/22	(2006.01
A61M 5/14	(2006.01
A61M 5/168	(2006.01
A61M 5/34	(2006.01

- (52) U.S. Cl.
- (58) Field of Classification Search CPC A61M 2039/261; A61M 2039/262; A61M 2039/263; A61M 2039/267; A61M 2039/268; A61M 2005/3128
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,457,052	Α	12/1948	Le Clair
2.485.006	Α	10/1949	Main. Jr. et al.
2.842.382	Α	7/1958	Franck
2,931,668	Α	4/1960	Baley
2.968.497	Α	1/1961	Treleman
3.127.892	Α	4/1964	Bellamy, Jr. et al.
3,304,047	Α	2/1967	Martin
3,334,860	Α	8/1967	Bolton, Jr.
3,538,950	Α	11/1970	Porteners
3,707,972	Α	1/1973	Villari et al.
3,729,031	Α	4/1973	Baldwin
3,824,556	Α	7/1974	Berkovits et al.
3,986,508	Α	10/1976	Barrington
4,055,179	Α	10/1977	Manschot et al.
4,066,067	Α	1/1978	Micheli
4,076,285	Α	2/1978	Martinez
4,080,965	Α	3/1978	Phillips
4,084,606	Α	4/1978	Mittleman
4,121,585	Α	10/1978	Becker, Jr.
4,133,441	Α	1/1979	Mittleman et al.
4,143,853	Α	3/1979	Abramson
4,150,845	Α	4/1979	Kopacz et al.
4,187,848	Α	2/1980	Taylor
4,195,632	Α	4/1980	Parker et al.
4,233,982	Α	11/1980	Bauer et al.
4,245,635	Α	1/1981	Kontos
4,324,239	Α	4/1982	Gordon et al.
4,334,551	Α	6/1982	Pfister
4,340,049	Α	7/1982	Munsch
4,379,458	Α	4/1983	Bauer et al.
4,387,879	А	6/1983	Tauschinski
4,397,442	Α	8/1983	Larkin

4 400 050 4	0/1004	D 1 1
4,430,073 A	2/1984	Bemis et al.
4,436,125 A	3/1984	Blenkush
4.457.749 A	7/1984	Bellotti et al.
4 511 359 A	4/1985	Vaillancourt
4,520,026 A	0/1005	Vaniancourt
4,558,850 A	9/1985	Kruetten
4,541,457 A	9/1985	Blenkush
4.576.359 A	3/1986	Oetiker
4 610 469 A	0/1086	Wolff-Mooii
4,010,409 A	10/1000	D-+-1-1
4,019,040 A	10/1980	Potoisky et al.
4,623,332 A	11/1986	Lindmayer et al.
4.629.159 A	12/1986	Wellenstam
4 660 803 A	4/1087	Johnston et al
4,000,805 A	5(1007	
4,662,878 A	5/1987	Lindmayer
4,673,400 A	6/1987	Martin
4.700.744 A	10/1987	Rutter et al.
4 722 602 A	2/1088	Dlummor
4,723,003 A	2/1900	
4,723,948 A	2/1988	Clark et al.
4,728,075 A	3/1988	Paradis
4 745 950 A	5/1988	Mathieu
4759022 A	7/1000	Varmillian
4,738,025 A	//1900	Verminion
4,774,964 A	10/1988	Bonaldo
4,774,965 A	10/1988	Rodriguez et al.
4 781 702 A	11/1988	Herrli
4 904 015 4	2/1080	A 11-1
4,804,015 A	2/1989	Aldinsson
4,816,024 A	3/1989	Sitar et al.
4.819.692 A	4/1989	Olson et al.
4 834 271 A	5/1080	Litwin
4,034,271 A	5/1969	
4,844,512 A	7/1989	Gahwiler
4,862,913 A	9/1989	Wildfang
4.863.201 A	9/1989	Carstens
1 882 182 A	11/1080	Lindmayor
4,005,405 A	11/1909	Chiunayer
4,915,687 A	4/1990	Sivert
4,917,669 A	4/1990	Bonaldo
4.935.010 A	6/1990	Cox et al.
4 0 40 7 45 A	8/1000	McKeen
4,949,745 A	0/1990	Nickeon
4,950,260 A	8/1990	Bonaldo
D313,277 S	12/1990	Haininig
D314 050 S	1/1991	Sone
5 006 114	4/1001	Degene et el
5,000,114 A	4/1991	Rogers et al.
5,021,059 A	6/1991	Kensey et al.
5.047.021 A	9/1991	Utterberg
5 065 783 A	11/1991	Ogle II
5,065,705 M	11/1001	Drop
5,000,280 A	11/1991	Ryan
5,070,885 A	12/1991	Bonaldo
5.083.819 A	1/1992	Bvnum
5 098 385 4	3/1002	Walsh
5,000,000 M	4/1002	Denalde
5,108,576 A	4/1992	Bonaldo
5,122,123 A	6/1992	Vaillancourt
5.139.483 A	8/1992	Rvan
5 147 333 A	9/1992	Raines
5,147,555 11	10/1002	Danalda
5,154,705 A	10/1992	Bonaldo
5,176,406 A	1/1993	Straghan
RE34.223 E	4/1993	Bonaldo
5 199 948 A	4/1993	McPhee
5 201 717 A	4/1002	Whatt at al
5,201,717 A	4/1993	wyatt et al.
5,201,726 A	4/1993	Kling
5,203,775 A	4/1993	Frank et al.
5.211.634 A	5/1993	Vaillancourt
5 215 537 A	6/1003	I vnn et el
5,215,557 A	0/1993	
5,215,558 A	6/1993	Larkin
5,242,393 A	9/1993	Brimhall et al.
5.242.425 A	9/1993	White et al.
5 251 873 A	10/1003	Atkinson et al
5,251,075 A	12/1002	Thamas at al
5,209,771 A	12/1993	Thomas et al.
5,273,533 A	12/1993	Bonaldo
5.279.571 A	1/1994	Larkin
5 281 206 1	1/100/	Lonez
5,201,200 A	2/1004	Lopez
3,284,475 A	2/1994	маска
5,295,657 A	3/1994	Atkinson
5.301.686 A	4/1994	Newman
5 206 242 4	4/1004	Domalda
5,500,245 A	4/1994	Donaido
5,312,377 A	5/1994	Dalton
5.324.270 A	6/1994	Kavan et al
5 220 225 *	7/1004	Wooner et -1
5,550,255 A	7/1994	wagner et al.
5,330,450 A	7/1994	Lopez
5.334.159 A	8/1994	Turkel
5 3/1/ /1/ 4	0/1004	Lonez at al
5,544,414 A	9/1994	Lopez et al.
5,360,413 A	11/1994	Leason et al.
		X X X X X A A

(56) **References** Cited

U.S. PATENT DOCUMENTS

5 380 306 1	1/1005	Brinon
5,380,300 A	1/1995	Littorhorg
5,585,572 A	1/1993	Otterberg
5,390,898 A	2/1995	Smedley et al.
5,391,150 A	2/1995	Richmond
5,395,348 A	3/1995	Ryan
5,397,314 A	3/1995	Farley et al.
5,400,500 A	3/1995	Behnke et al.
5,401,245 A	3/1995	Haining
5.402.826 A	4/1995	Molnar et al.
5.402.982 A	4/1995	Atkinson et al.
5 405 323 A	4/1995	Rogers et al
5 405 331 A	4/1005	Behnke et al
5 405 222 A	4/1005	Dishmond
5,405,555 A	4/1993 5/1005	De de motoria
5,411,499 A	5/1995	Dudar et al.
5,417,673 A	5/1995	Gordon
5,423,791 A	6/1995	Bartlett
5,425,465 A	6/1995	Healy
5,433,330 A	7/1995	Yatsko et al.
5,439,451 A	8/1995	Collinson et al.
5,441,487 A	8/1995	Vedder
5,445,623 A	8/1995	Richmond
5,447,177 A	9/1995	Ricken et al.
5.456.668 A	10/1995	Ogle, II
5 456 675 A	10/1995	Wolbring et al
5 462 255 A	10/1005	Rosen et al
5 464 200 A	11/1005	Rosen et al.
5,404,599 A	11/1995	Massar
5,470,319 A	11/1993	Mayer
5,470,327 A	11/1995	Heigren et al.
5,474,536 A	12/1995	Bonaldo
5,480,393 A	1/1996	Bommarito
5,489,274 A	2/1996	Chu et al.
5,492,147 A	2/1996	Challender et al.
5,501,426 A	3/1996	Atkinson et al.
5,507,744 A	4/1996	Tay et al.
5.514.177 A	5/1996	Kurz et al.
5.518.026 A	5/1996	Beniev
5.520.665 A	5/1996	Fleetwood
5 520 666 A	5/1996	Choudhury et al
5 527 284 A	6/1006	Obnemus et al
5,527,204 A	7/1006	Athingon of al
5,555,700 A	7/1990	Atkinson et al.
5,555,985 A	7/1990	Haining Manufactoria
5,533,996 A	7/1996	Murphey et al.
5,535,785 A	7/1996	werge et al.
5,540,661 A	7/1996	Tomisaka et al.
5,549,566 A	8/1996	Elias et al.
5,549,577 A	8/1996	Siegel et al.
5,549,651 A	8/1996	Lynn
5,552,118 A	9/1996	Mayer
5,555,908 A	9/1996	Edwards et al.
5.569.235 A	10/1996	Ross et al.
5 573 516 A	11/1996	Typer
5 575 769 A	11/1996	Vaillancourt
5 578 050 A	11/1006	Patzer
5 5 8 4 8 10 A	12/1006	Konfer
5,504,015 A	1/1007	Stavana
5,591,157 A	1/1997	Stevens
5,591,143 A	1/1997	frombley, ill et al.
5,597,536 A	1/1997	Mayer
5,616,129 A	4/1997	Mayer
5,616,130 A	4/1997	Mayer
RE35,539 E	6/1997	Bonaldo
5,643,224 A	7/1997	Szapiro et al.
5,645,538 A	7/1997	Richmond
5.651.776 A	7/1997	Appling et al.
5.674.206 A	10/1997	Allton et al.
5 676 346 A	10/1997	Leinsing
5 685 866 4	11/1007	Lonez
5 685 868 4	11/1007	Lundavist
5,005,000 A	12/1007	Daradia
5,099,821 A	12/1997	Lamar
5,700,248 A	12/1997	Lopez
5,702,374 A	12/1997	Johnson
5,709,243 A	1/1998	Wells et al.
5,735,826 A	4/1998	Richmond
5,738,144 A	4/1998	Rogers
5.749.861 A	5/1998	Guala et al
DE35 8/1 E	7/1000	Fronk at al
NE33,041 E	11 1990	TTAIK OF AL.

5.782.818	А	7/1998	Werschmidt et al.
5 784 750	Δ	7/1008	Sankovic et al
5 785 602	<u>A</u>	7/1008	Unining
5,785,095	A	//1998	Haining
5,788,215	A	8/1998	Ryan
5,806,831	Α	9/1998	Paradis
5.810.398	А	9/1998	Matkovich
5 814 024	Â	0/1008	Thompson et al
5,014,024	<u>,</u>	10/1000	Manipson et al.
5,820,601	A	10/1998	Mayer
5,820,614	Α	10/1998	Erksine et al.
5.830.189	Α	11/1998	Chang
5 839 715	Δ	11/1008	Leinsing
5,039,713	<u>л</u>	12/1008	D'shared
5,848,994	A	12/1998	Richmond
5,947,954	Α	9/1999	Bonaldo
6,029,946	Α	2/2000	Doyle
6 036 171	Δ	3/2000	Weinheimer et al
6 030 302	Â	3/2000	Cote Sr et al
0,039,302	A	3/2000	Cole, SI. et al.
6,041,805	Α	3/2000	Gydesen et al.
6,050,978	Α	4/2000	Orr et al.
6.063.062	Α	5/2000	Paradis
6 068 011	Α	5/2000	Paradis
6,069,617	<u>^</u>	5/2000	Dishmand
0,008,017	A	5/2000	Richmond
6,079,432	Α	6/2000	Paradis
6,106,502	Α	8/2000	Richmond
6,113,068	Α	9/2000	Ryan
6 142 446	Δ	11/2000	Leinsing
6 152 012	<u>A</u>	11/2000	Ealth at al
0,152,915	A	1/2000	renn et al.
6,168,137	BI	1/2001	Paradis
6,170,522	B1	1/2001	Tanida
6.171.287	B1	1/2001	Lvnn et al.
6 180 850	R1	2/2001	Rohrbough et al
6,105,055		2/2001	D' 1 1
0,200,800	BI	3/2001	Richmond
6,221,029	BI	4/2001	Mathis et al.
6,224,578	B1	5/2001	Davis et al.
6.242.393	B1	6/2001	Ishida et al.
6 245 048	B1	6/2001	Fangrow et al
6,245,046	DI	0/2001	Darda
6,290,206	BI	9/2001	Doyle
6,299,132	BI	10/2001	Weinheimer et al.
6,325,100	B1	12/2001	Bunschoten et al.
6.402.207	B1	6/2002	Segal et al.
6 428 520	B1	8/2002	Lopez
6,421,210		8/2002	D allan at al
6,431,219	ы	8/2002	Redler et al.
6,485,472	B1	11/2002	Richmond
6,499,719	B1	12/2002	Clancy et al.
6.508.792	B2	1/2003	Szames et al.
6 508 807	DI	1/2003	Botors
0,308,807	DI	1/2003	releis
0,541,802	BZ	4/2003	Doyle
6,543,745	B1	4/2003	Enerson
6.581.906	B2	6/2003	Pott et al.
6 585 229	B2	7/2003	Cote et al
6 505 064	B2	7/2003	Finley et al
0,393,904		7/2003	Finite et al.
6,595,981	B2	7/2003	Huet
6,609,696	B2	8/2003	Enerson
6,612,624	B1	9/2003	Segal et al.
6.666.852	B2	12/2003	Niedospial. Jr.
6 673 059	B2	1/2004	Guala
6 6 6 5 8 1 7	D2 D1	2/2004	Cuala
0,095,817	DI	2/2004	Fangrow
6,745,998	B2	6/2004	Doyle
6,808,161	B1	10/2004	Hishikawa
6.840.501	B2	1/2005	Dovle
6 843 513	B2	1/2005	Guala
6 860 426	D2	2/2005	Conom
0,809,420	DZ D2	5/2005	Ganem
6,875,205	B2	4/2005	Leinsing
6,893,056	B2	5/2005	Guala
6,899,315	B2	5/2005	Maiville et al.
6 911 025	B2	6/2005	Miyahara
6 055 660	D2	10/2005	Curatohorra
0,955,009		11/2005	Curutenany
0,904,400	B2	11/2005	Doyle
7,004,934	B2	2/2006	Vaillancourt
7,037,302	B2	5/2006	Vaillancourt
7.040 598	B2	5/2006	Ravbuck
7 044 441	D2	5/2000	Davia
7,044,441	Б 2	5/2006	Doyle
7,100,891	B2	9/2006	Doyle
7,125.396	B2	10/2006	Leinsing et al.
7 137 654	B2	11/2006	Segal et al
7,137,034	D2	11/2000	Digar et al.
7,140,592	В2	11/2006	rnillips
7,160,272	B1	1/2007	Eyal et al.
7.182.313	B2	2/2007	Dovle
7 105 229	B2	3/2007	Tiberghien et al
7,193,228	D2	5/2007	noeigmen et al.
1 2/1/ 2/10	B2	1/2007	Leinsing et al.

(56) **References** Cited

U.S. PATENT DOCUMENTS

7 306 107 B2	12/2007	Parrino et al
7,500,107 D2	12/2007	
7,306,198 B2	12/2007	Doyle
7,306,566 B2	12/2007	Raybuck
7 316 679 B2	1/2008	Bierman
7,510,075 D2	2/2008	Distribution
7,347,458 B2	3/2008	Rome et al.
7,350,764 B2	4/2008	Raybuck
7 361 164 B2	4/2008	Simpson et al
7,07,484 D2	2/2000	Zimon
7,497,484 DZ	3/2009	Ziman
7,559,530 B2	7/2009	Korogi et al.
7.588.563 B2	9/2009	Guala
7 628 781 82	12/2000	Dov of al
7,028,781 D2	12/2009	Kuy et al.
7,645,274 B2	1/2010	whitley
7.651.481 B2	1/2010	Ravbuck
7,666,170, B2	2/2010	Guala
7,000,170 D2	2/2010	Ouala Dia 1
7,722,090 BZ	5/2010	Burton et al.
7,758,566 B2	7/2010	Simpson et al.
7 766 304 B2	8/2010	Phillins
7766 207 02	8/2010	Romany at al
7,700,897 B2	8/2010	Kallisey et al.
7,803,139 B2	9/2010	Fangrow, Jr.
7.803.140 B2	9/2010	Fangrow, Jr.
7 815 614 B2	10/2010	Eangrow Ir
7,015,014 D2	11/2010	Tangiow, 51.
7,837,038 BZ	11/2010	Cote et al.
7,857,805 B2	12/2010	Raines
7.875.019 B2	1/2011	Barron et al.
7 076 532 P2	7/2011	Vitani at al
7,970,332 BZ	//2011	Kitani et al.
7,998,134 B2	8/2011	Fangrow et al.
8.066.692 B2	11/2011	Simpson et al.
8 177 772 B2	5/2012	Christensen et al
8,177,772 B2	5/2012	
8,196,614 B2	6/2012	Kriheli
8,211,069 B2	7/2012	Fangrow, Jr.
8 225 826 B2	7/2012	Horppu et al
8,225,820 D2	7/2012	Thomppu et al.
8,231,307 B2	//2012	Tennican et al.
8,262,628 B2	9/2012	Fangrow, Jr.
8.281.824 B2	10/2012	Molema et al.
8 286 026 P2	10/2012	Kitani at al
8,280,930 B2	10/2012	Kitalli et al.
8,287,513 B2	10/2012	Elistrom et al.
8.414.554 B2	4/2013	Garfield et al.
8 414 555 B2	4/2013	Garfield et al
8,454,570 D2		East and the Later
8,454,579 B2	6/2013	Fangrow, Jr.
8,556,868 B2	10/2013	Simpson et al.
8.647.310 B2	2/2014	Fangrow, Jr. et al.
8 670 000 B2	3/2014	Anderson et al
8,079,090 B2	5/2014	Alluerson et al.
8,721,628 B2	5/2014	Ziman
8,777,908 B2	7/2014	Fangrow, Jr.
8 777 909 B2	7/2014	Fangrow Ir
8,777,505 B2	10/2014	I angrow, sr.
8,804,737 BZ	10/2014	Hasegawa et al.
8,888,758 B2	11/2014	Mansour et al.
8.899.267 B2	12/2014	Diodati et al.
9 114 242 B2	8/2015	Eangrow et al
9,114,242 D2	0/2015	Tangiow et al.
9,126,028 B2	9/2015	Fangrow et al.
9.126.029 B2		U
J 120 022 D2	9/2015	Fangrow et al.
9.168.366 B2	9/2015 10/2015	Fangrow et al. Fangrow et al.
9,168,366 B2 9,345,641 B2	9/2015 10/2015 5/2016	Fangrow et al. Fangrow et al.
9,168,366 B2 9,345,641 B2	9/2015 10/2015 5/2016	Fangrow et al. Fangrow et al. Kraus et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2	9/2015 10/2015 5/2016 6/2016	Fangrow et al. Fangrow et al. Kraus et al. Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2	9/2015 10/2015 5/2016 6/2016 3/2017	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow Ir
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,913,945 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow Fangraw, Jr.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,940 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,930 B2 9,974,940 B2 10,046,154 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,939 B2 9,974,940 B2 10,046,154 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Simpson
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow Fangraw, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,930 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,939 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow Fangraw, Jr. Fangrow Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,913,945 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716 928 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 10/2018 12/2018	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow et al
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,930 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020 7/2020	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,974,939 B2 9,974,939 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2	9/2015 10/2015 5/2016 6/2016 3/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020 7/2020	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangraw, Jr. Fangrow, Jr. Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018 12/2018 6/2020 11/2020 6/2002	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow et al. Fangrow y. Fangrow y. Fangrow, Jr. Niedospial, Jr.
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,930 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0066978 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2018 5/2018 5/2018 5/2018 8/2018 5/2018 8/2018 12/2018 6/2020 7/2020 11/2020 6/2002 4/2003	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow et al. Simpson Fangrow F
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,974,939 B2 9,974,939 B2 9,974,939 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0066978 A1	9/2015 10/2015 5/2016 6/2016 3/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020 7/2020 11/2020 6/2002 4/20003 7/2003	Fangrow et al. Fangrow et al. Fangrow et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow, Jr. Niedospial, Jr. Enerson Doule
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,716,928 B2 2002/0066715 A1 2003/0066978 A1 2003/0136932 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020 7/2020 11/2020 6/2002 4/2003 7/2003	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow tal. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow, Jr. Niedospial, Jr. Enerson Doyle
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,939 B2 10,046,154 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0066978 A1 2003/0136932 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2018 5/2018 5/2018 5/2018 5/2018 8/2018 5/2018 6/2020 7/2020 11/2020 6/2002 4/2003 7/2003 11/2003	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangraw, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fang
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,974,940 B2 10,046,154 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0066978 A1 2003/0208165 A1 2004/0074541 A1	9/2015 10/2015 5/2016 6/2016 3/2017 7/2017 7/2017 8/2017 3/2018 4/2018 5/2018 5/2018 8/2018 10/2018 12/2018 10/2018 12/2018 12/2018 12/2018 12/2010 6/2020 4/2003 7/2020 11/2020 6/2002 4/2003 7/2003	Fangrow et al. Fangrow et al. Fangrow et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow, Jr. Niedospial, Jr. Enerson Doyle Christensen et al. Sharpe
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,707,346 B2 9,913,945 B2 9,933,094 B2 9,974,940 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,697,570 B2 10,716,928 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0066978 A1 2003/0136932 A1 2003/028165 A1 2003/028165 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2017 3/2018 4/2018 5/2018 5/2018 5/2018 5/2018 10/2018 12/2018 6/2020 7/2020 11/2020 6/2002 4/2003 7/2003 11/2003	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Simpson et al. Fangrow Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow Fangro
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,724,504 B2 9,913,945 B2 9,933,094 B2 9,974,939 B2 9,974,939 B2 10,046,154 B2 10,046,154 B2 10,105,492 B2 10,156,306 B2 10,697,570 B2 10,716,928 B2 10,842,982 B2 2002/0066715 A1 2003/0208165 A1 2003/0208165 A1 2004/0074541 A1 2004/0124388 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2018 5/2018 5/2018 5/2018 5/2018 5/2018 8/2018 10/2018 10/2018 6/2020 7/2020 11/2020 6/2002 4/2003 11/2003 11/2003 4/2004 7/2004	Fangrow et al. Fangrow et al. Kraus et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow Fangraw, Jr. Fangrow Fangrow, Jr. Fangrow et al. Simpson Fangrow Fan
9,168,366 B2 9,345,641 B2 9,358,379 B2 9,592,344 B2 9,636,492 B2 9,707,346 B2 9,974,504 B2 9,974,940 B2 10,046,154 B2 10,046,154 B2 10,054,929 B2 10,156,306 B2 10,716,928 B2 10,716,928 B2 10,716,928 B2 2002/0066715 A1 2003/0136932 A1 2003/0126316 A1 2004/0074541 A1 2004/0074541 A1 2004/0124388 A1	9/2015 10/2015 5/2016 6/2016 3/2017 5/2017 7/2017 8/2017 8/2018 5/2018 5/2018 5/2018 5/2018 8/2018 10/2018 12/2018 6/2020 7/2020 11/2020 6/2002 4/2003 7/2003 11/2003 11/2004 7/2004 7/2004	Fangrow et al. Fangrow et al. Fangrow et al. Fangrow Simpson et al. Fangrow, Jr. Simpson et al. Fangrow, Jr. et al. Fangrow, Jr. Fangrow, Jr. Fangrow, Jr. Fangrow et al. Simpson Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow Fangrow, Jr. Niedospial, Jr. Enerson Doyle Christensen et al. Sharpe Kiehne Phillips

2004/0244848	A1	12/2004	Maldavs
2005/0015075	A1	1/2005	Wright et al.
2005/0090805	A1	4/2005	Shaw et al.
2005/0124942	Al	6/2005	Richmond
2005/0228362	A1	10/2005	Vaillancourt
2006/0025751	A1	2/2006	Roy et al.
2006/0058734	A1	3/2006	Phillips
2006/0065873	A1	3/2006	Dovle
2006/0129109	Al	6/2006	Shaw et al.
2006/0142730	A1	6/2006	Proulx et al.
2006/0142735	A1	6/2006	Whitley
2006/0149213	AI	7/2006	Ravbuck
2006/0157984	Al	7/2006	Rome et al
2006/0161115	AI	7/2006	Fangrow
2006/0202146	A1	9/2006	Dovle
2006/0202140	A1	11/2006	Nordaren
2000/0233084	A1	2/2007	Guala
2007/0043334	A1	4/2007	Guala
2007/0088292	AI	4/2007	Fangrow
2007/0088293	AI	4/2007	Fangrow
2007/0088294	AL	4/2007	Fangrow
2007/0088327	AI	4/2007	Guala
2007/0102923	AI	5/2007	Niemela
2007/0179453	AI	8/2007	Lim et al.
2008/0103485	Al	5/2008	Kruger
2008/0190485	Al	8/2008	Guala
2008/0290657	Al	11/2008	McKeon, III
2009/0177170	Al	7/2009	Kitani et al.
2010/0063482	A1	3/2010	Mansour et al.
2010/0174242	A1	7/2010	Anderson et al.
2010/0253070	A1	10/2010	Cheon et al.
2011/0046572	A1	2/2011	Fangrow
2011/0062703	A1	3/2011	Lopez
2011/0175347	A1	7/2011	Okiyama
2011/0306931	A1	12/2011	Kamen et al.
2012/0031515	A1	2/2012	Whitaker
2012/0046636	A1	2/2012	Kriheli
2012/0089101	A1	4/2012	Carlyon et al.
2012/0316536	A1	12/2012	Carrez et al.
2013/0006211	A1	1/2013	Takemoto
2013/0035668	A1	2/2013	Kitani et al.
2013/0317483	AI	11/2013	Reichart et al
2013/0020792	Al	1/2014	Kraus et al
2014/0246616	AI	9/2014	Fangrow
2015/0051555	A 1	2/2015	Fangrow Ir
2015/0258324	A 1	0/2015	Chida et al
2015/0258524	A 1	7/2015	Engrow Ir of al
2010/0213910		0/2016	Fangrow, JI. et al.
2010/0205507	AI	9/2010	Faligiow et al.
2017/0296801	AI	1/2017	Fangrow, Jr.
2018/0015275	AI	1/2018	Fangrow
2018/0030524	AI	2/2018	Fangrow, Jr.
2018/01/2190	AI	6/2018	Fangrow
2018/0333568	AI	11/2018	Fangrow, Jr.
2019/0038886	AI	2/2019	Fangrow
2019/0078712	Al	3/2019	Fangrow
2020/0215319	A1	7/2020	Fangrow, Jr.
2020/0284385	A1	9/2020	Fangrow
2021/0162191	Al	6/2021	Fangrow
2021/0252267	Al	8/2021	Fangrow

FOREIGN PATENT DOCUMENTS

EP	0 368 473 A2	5/1990
EP	0 791 371	8/1997
EP	0 795 342	9/1997
EP	1 050 318	11/2000
EP	1 946 792	7/2008
EP	2 123 322	11/2009
GB	2 116 277	9/1983
GB	2 118 440	11/1983
GB	2 353 078	2/2001
JP	56-72659 U1	6/1981
JP	58-13216	1/1983
JP	59-41429	3/1984
JP	60-89488	6/1985
JP	62-65779	4/1987
JP	63-175383	11/1988
JP	11-311234	11/1999
JP	2001-187990 A	7/2001
JP	2004-000483 A	1/2004

(56) References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 1988/08499	11/1988
WO	WO 1995/32748	12/1995
WO	WO 2001/03756	1/2001
WO	WO 2001/23026	4/2001
WO	WO 2002/096500	12/2002
WO	WO 2003/013646	2/2003
WO	WO 2004/060474	7/2004
WO	WO 2004/082756	9/2004
WO	WO 2006/076656	7/2006
WO	WO 2006/088858	8/2006
WO	WO 2006/124756	11/2006
WO	WO 2007/008511	1/2007
WO	WO 2007/112944	10/2007
WO	WO 2008/144447	11/2008
WO	WO 2009/095760	8/2009
WO	WO 2010/071848	6/2010
WO	WO 2011/139995	11/2011
WO	WO 2013/036854	3/2013

OTHER PUBLICATIONS

Air Embolism and Exsanguination from Separation.of Two-Piece Side Port/Hemostasis Valve Cardiac Catheter Introducers, ECRI Institute, Jan. 1995, in 2 pages, http://www.mdsr.ecri.org/summary/ detail.aspx?doc id=8098. EPO Search Report re EP Application No. 08 755 612.2, dated Feb. 23, 2012 in 5 pages.

EPO Examination Report re EP Application No. 08 755 612.2, dated Nov. 20, 2013 in 5 pages.

EPO Examination Report re EP Application No. 08 755 612.2, dated Dec. 5, 2012 in 6 pages.

Injection Site, Molded Products, Inc., Apr. 2, 2004, in 1 page, https://web.archive.org/web/20040402123354/https://www.moldedproducts.com/injectionsite.htm.

International Search Report for PCT/US2006/026124, dated Mar. 3, 2007 in 5 pgs.

International WrittenOpinion for PCT/US2006/026124, dated Jan. 10, 2008 in 11 pgs.

International Search Report and Written Opinion of International Application No. PCT/US2008/063797 dated Dec. 30, 2008 in 21 pages.

International Preliminary Report on Patentability, International Application No. PCT/US2008/063797 dated Nov. 17, 2009 in 11 pages. International Search Report and Written Opinion for International Application No. PCT/US2004/042723, dated Jun. 28, 2005 in 16 pages.

International Written Opinion of International Application No. PCT/US2004/042723 dated Jul. 3, 2006 in 10 pages.

ICU Medical, Inc. U.S. Appl. No. 11/417,882, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,923, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,671, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,648, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,909, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 11/417,909, filed May 3, 2006. ICU Medical, Inc. U.S. Appl. No. 15/789,242, filed Oct. 20, 2016.



FIG. 1



FIG. 2







FIG. 5



FIG. 6



FIG. 7



FIG. 8



FIG. 9



FIG. 10



FIG. 11



FIG. 12



FIG. 13



FIG. 14



FIG. 15

40

MEDICAL CONNECTOR WITH INTERNAL VALVE MEMBER MOVABLE WITHIN MALE PROJECTION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/916,778, filed Mar. 9, 2018, now U.S. Pat. 10No. 10,105,492, which is a continuation of U.S. patent application Ser. No. 15/648,147, filed Jul. 12, 2017, now U.S. Pat. No. 9,913,945, which is a continuation of U.S. patent application Ser. No. 14/052,592, filed Oct. 11, 2013, now U.S. Pat. No. 9,707,346, which is a continuation of U.S. patent application Ser. No. 13/305,663, filed Nov. 28, 2011, now U.S. Pat. No. 8,556,868, which is a continuation of U.S. patent application Ser. No. 12/789,255, filed May 27, 2010, now U.S. Pat. No. 8,066,692, which is a continuation of U.S. patent application Ser. No. 10/584,920, filed Dec. 28, 2006, 20 now U.S. Pat. No. 7,758,566, which is the National Stage Entry of International Application No. PCT/US04/42723, filed Dec. 21, 2004, which claims the benefit of U.S. Provisional Application No. 60/532,916, filed Dec. 30, 2003; the entire contents of all of which are hereby incor- 25 porated by reference herein and made a part of this specification. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to medical fluid delivery ³⁵ valves and more particularly to valve assemblies for use with syringes or other medical dispensing devices.

Description of the Related Art

Syringes are commonly used to deliver medications and other biological fluids to a patient. The syringe typically has a plunger which is sealingly engaged with an outer cylindrical chamber to form an inner fluid-receiving chamber, A 'male' luer fitting is usually provided at a delivery end of the 45 chamber which receives a female luer fitting with a needle assembly or the like. The fluid channel joining the cavity to the luer fitting is usually open, so that when the needle is removed, the cavity is open to the environment. This is problematic since many medications and biological fluids ⁵⁰ are sensitive (or can degrade when exposed) to the environment.

It is therefore an object of the present invention to provide a novel valve assembly for use with a syringe or other medical dispensing devices, enabling the latter to be closed ⁵⁵ to the environment when in an unattached condition.

SUMMARY OF THE INVENTION

In one of its aspects, the present invention provides a 60 valve assembly comprising a male luer end portion, a female luer end portion and a channel for the transfer of fluids between the male and female luer end portions, valve means movable between a closed position and an open position, biasing means for biasing the valve means toward the closed 65 position, and actuating means extending into the male luer end portion and coupled to the valve means to actuate the

valve means when a female luer end portion of a medical accessory is coupled with the male luer end portion.

In an embodiment the male luer end portion has an inner projection and outer threaded sheath which is spaced there-

from to receive the female luer end portion therebetween. The actuating means includes an actuating member positioned between the outer threaded sheath and the inner projection.

In an embodiment, the valve means includes a valve seat and a valve member moveable relative thereto. The channel includes a first channel portion adjacent the female luer end portion and the inner projection includes a second channel portion. The valve member has a valve channel portion in fluid communication with the first and second channel portions. The valve seat is formed in the second channel portion and the valve member is integrally formed with the female luer end portion.

In one embodiment, the valve member includes an anchor flange extending outwardly toward an inner surface of the housing portion. In this case, the housing portion is coupled to the male luer end portion for movement therewith relative to the valve member. The male luer end portion engages the anchor flange when the valve means is in the closed position and the male luer end portion is spaced from said anchor flange when the valve means is in the open position. The housing portion terminates at an end region adjacent the female luer end portion, the biasing means includes a compression spring located within the housing between the end region and the outer anchor flange.

In another of its aspects, the present invention provides a medical dispensing device comprising a body having a chamber therein to contain a fluid material, a valve assembly in fluid communication with the chamber, the valve assembly having a male coupling member for engaging a female coupling member on a medical accessory to form a fluid coupling between the medical dispensing device and the medical accessory, the valve assembly further comprising flow control means operable to control fluid flow through the male coupling member, the flow control means being operable to be displaced by the female coupling member to open the male coupling member when female coupling member is operatively connected therewith, the flow control means being operable to be displaced by the female coupling member to close the male coupling member when the female coupling member is disconnected therefrom.

In one embodiment, the male coupling member includes an inner male portion and an outer sheath portion spaced therefrom to form a passage there between for receiving the female coupling member, the flow control means including at least one valve actuating portion positioned in the passage to abut the female coupling member and to displace the valve member during the travel of the female coupling member along the passage. The valve assembly includes a valve member and a valve seat, wherein the valve member is positioned against the seat to close the male coupling member. The valve actuating portion includes a pair of abutment elements which are spaced from one another along the passage to receive the female coupling member there between, wherein the pair of abutment elements are operable to travel with the female coupling member along the passage.

In one embodiment, the actuating portion is longitudinally oriented relative to the passage and the abutment elements are positioned along the actuating portion. 5

10

The valve member includes a back plate and a plurality of actuating portions equally spaced on the back plate, each of the actuating portions having first and second abutment elements.

In one embodiment, the valve actuating portion includes a locking flange which is adjacent one of the abutment elements. The valve assembly includes a locking seat to receive the locking flange when the male coupling member is in the closed position. The actuating portion has a distal end region, the locking flange being located adjacent the distal end region and the locking seat is formed in the outer sheath portion. The actuating portion is thus arranged to flex in order to displace the locking flange from the locking seat.

In yet another aspect, the present invention provides a medical dispensing device comprising a body having a chamber therein to contain a fluid material, a valve assembly in fluid communication with the chamber, the valve assembly having a male coupling member for engaging a female coupling member on a medical accessory to form a fluid coupling between the medical dispensing device and the medical accessory, the male coupling member including a 20 projection and an outer valve member movable relative to the projection, the projection and the outer valve member forming a fluid channel there between, a sheath portion encircling the projection and spaced therefrom to form a passage to receive the female coupling member, the valve 25 member being engageable with the female coupling member and movable relative to the projection to open the fluid channel when the female coupling member is connected with the male coupling member.

In one embodiment, the valve member forms an outer 30 surface of the male coupling portion.

In an embodiment, biasing means is provided to bias the valve member toward an engaged position with the projection to close the fluid channel. In this particular case, the passage ends at an inner wall and the biasing means includes a spring located between the inner wall and the valve ³⁵ member.

In one embodiment, the projection is fixed to the body and includes an inner passage, the inner passage having one end which is open to the chamber and another end which is open to the fluid channel. The projection also includes an enlarged 40 end portion, the valve member including an outer portion arranged to engage the enlarged end portion to close the fluid channel. In this case the enlarged end portion and the outer end portion on the valve member have mating bevelled surfaces.

In one embodiment, the female coupling member has a leading segment, the valve member being dimensioned to fit within the leading segment.

Preferably, the medical dispensing device includes such items as a syringe, an IV bottle, an IV line, a powder and/or atomized fluid and/or gas inhalant dispenser, an implant delivery dispenser, a ventilator, a syringe pump, an intubation tube, a gastrointestinal feeding tube or a plurality and/or a combination thereof.

Preferably, the medical material is in solid, liquid or gaseous form or a combination thereof and has beneficial ⁵⁵ properties to enhance life, to promote health, to cure and/or treat a disease, condition or ailment, to monitor and/or indicate a bodily function or a combination thereof. For example, the medical material may be useful for, among others, IV therapy, implantation, stem cell therapy, oncology ⁶⁰ therapy, blood transfusion and/or organ transplantation.

BRIEF DESCRIPTION OF THE DRAWINGS

Several preferred embodiments of the present invention 65 will now be described, by way of example only, with reference to the appended drawings in which:

FIG. 1 is a perspective view of a syringe assembly;

FIG. **2** is a sectional view of a portion of the assembly of FIG. **1**;

FIGS. **3** and **4** are sectional views of the assembly of FIG. **1** in two alternate operative positions;

FIG. **5** is a fragmentary sectional perspective view of a portion of another syringe assembly;

FIGS. 6 and 7 are fragmentary perspective views of another syringe assembly;

FIGS. 8 to 12 are fragmentary sectional views of the syringe assembly of FIG. 6;

FIG. **13** is a fragmentary perspective view of yet another syringe assembly; and

FIGS. **14** and **15** are fragmentary sectional views of the ¹⁵ syringe assembly of FIG. **13** or portions thereof.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring to the figures, and in particular FIG. 1, there is provided a syringe assembly 10 comprising a syringe 12 and a valve unit 14. The syringe 12 has a chamber 20 containing a plunger 22 to form a cavity 24. Referring to FIG. 2, the cavity has an outlet 26 and the valve unit 14 is located downstream of the outlet 26 for coupling the cavity 24 with a medical accessory such as a needle 30 (as shown in FIGS. 3 and 4). The valve unit 14 has an outlet 32 and flow control means, as will be described, to control fluid flow through the outlet, the flow control means being operable to open the outlet when the coupling section is operatively connected with the medical accessory, the flow control means being operable to close the outlet when the valve unit is disconnected from the medical accessory and to remain closed until connected once again with a medical accessory.

In this case, the chamber 20 includes a first male luer end portion 34 adjacent the outlet 26 and the valve unit 14 includes a first female luer end portion 36 which is engageable with the male luer end portion 34. The valve unit 14 also includes a second male luer end portion 38 for coupling with the medical accessory 30.

Although the chamber 20 and the valve unit 14 are separate from one another in this case, it will be understood that they may, alternatively, be integrally formed, for example by combining the first male luer end portion 34 with the female luer end portion 36.

The valve unit 14 has a channel 42 for the transfer of fluids between the female and male luer end portions 36, 38. A valve means, in the form of a valve member 44 is located in the valve unit 14 and is movable between a first position (as shown in FIG. 2), in which the channel is closed, and a second position (as shown in FIG. 3), in which the channel is open. An actuating means, in the form of an actuating member 46 (shown in FIG. 2), extends outwardly from the valve member 44 and into the male luer end portion 38. The actuating member 46 is coupled to the valve member 44 to actuate it when a female luer end portion of the medical accessory 30 is engaged with the male luer end portion 38.

In the embodiment of FIGS. 1 to 4, the male luer end portion 38 has an outer threaded sheath 50 which is spaced from an inner projection 52. In this case, the actuating member 46 is positioned between the outer threaded sheath 50 and the inner projection 52. The valve member 44 includes a valve plug portion 54 moveable relative to a valve seat portion 56. The valve member 44 has an upper end which is integrally formed with the female luer end portion 36. An outer housing member 58 is slidably mounted on the valve member 44. In this case, the outer housing member 58

is joined to the male luer end portion **38**. The valve member **44** also has a valve channel **44***a* extending from the female luer end portion **36** to the valve plug portion **42** where it terminates at one or more transverse flow openings **44***b* to join with the channel **42**.

The valve member 44 includes an anchor flange 60, and the male luer end portion 38 seats, directly or indirectly, against the anchor flange 60 when the valve is in the closed position as viewed in FIG. 2. Conversely, the male luer end portion 38 is spaced from said anchor flange when the valve 10 is in the open position as shown in FIG. 3.

The outer housing **58** terminates at a radially inwardly directed end region **62** adjacent the female luer end portion **34** and a biasing means in the form of a compression spring **64** is located within the outer housing between the end 15 region **62** and the anchor flange **60** to bias the valve member toward the first position to close the valve unit.

An alternative arrangement is shown in FIG. 5. In this case, the valve unit 70 has a housing 72 which is integrally formed with the female luer end portion 74. A first channel 20 portion 76 is adjacent the female luer end portion 74 and a second channel portion 78 is adjacent a male luer end portion 80. In this case, the valve means includes a valve member 82 having a valve channel 84 in fluid communication with the first and second channel portion is formed at 90 in the second channel portion 78.

The valve member 82 includes a plug portion 92 which is movable relative to and within the second channel portion 78 for engaging the seat portion 90 to close the second 30 channel portion 78. The first channel portion 76 includes a tubular projection 94 extending from the female luer end portion 74. In this case, the valve channel 84 in the valve member 82 is coextensive with the first and second channel portions 76, 78. In this case, the tubular projection 94 is 35 slidably engaged with the valve member 82 within the valve channel 84 and sealed therein by way of seal 98. Likewise, the valve member 84 is sealed within the second channel portion 78 by way of seal 100.

The syringe assembly 10 is used as follows. First, the 40 valve unit 14 is joined to the syringe 12 by engaging the corresponding first male luer end portion 34 with the female luer end portion 36. In this condition, the second male luer end portion 38 is unattached with a medical accessory such as the needle 30 and the actuator 46 is fully extended into the 45 second male luer end portion 38 as shown in FIG. 2. Consequently, the valve member 44 is biased to its closed position, thereby engaging the valve plug portion 54 against the valve seat 56.

The needle **30** is then attached to the syringe by engaging 50 the female luer end portion on the needle 30 with the second male luer end portion 38. Doing so causes the female luer end portion on the needle 30 to abut and displace the actuating member 46, thereby causing the valve member 44 to be displaced upwardly (as viewed in FIG. 2) thereby 55 releasing the valve plug portion 54 from its sealed abutment with the valve seat 56 to open the valve channel. The plunger 22 may then be displaced outwardly to cause fluids in the proximity of the pointed end of the needle 30 to be drawn into the cavity 24, by a path starting at the valve seat 56 60 through the channel 42 to the transverse flow openings 44b, to the valve channel 44a and on through the female luer end portion and into the cavity 24. The needle 30 may then be removed causing the actuating member 46 to be displaced downwardly (as viewed in FIG. 2) causing the immediate 65 displacement of the valve plug portion to abut the seat 56 and thereby close the valve.

6

Another device is shown at 120 FIGS. 6 to 12, having a body 122 forming an inner chamber 124 therein to contain a fluid material. A valve assembly 126 is in fluid communication with the chamber 124 and has a male coupling member 128 for engaging a female coupling member 130 on a medical accessory (in this case a needle 132) to form a fluid coupling between the device 120 and the needle 132.

The valve assembly **126** is operable to control fluid flow through the male coupling member **128** and more particularly to be in an open position when the male coupling member **128** is operatively connected with the female coupling member **130** and, conversely, to be in a closed position when the male coupling member **128** is disconnected from the female coupling member **130**.

In this case, the body 122 and the valve assembly 126 are integrally formed and, as seen in FIG. 8, the latter includes a valve member 134 and a valve seat 136. The valve member 134 is shown in its position against the valve seat 136 to close the male coupling member 128, but for a very minor gap there between for illustrative purposes only.

The male coupling member 128 includes an inner male portion 140 having an inner fluid channel 140*a* and an outer sheath portion 142 spaced from the inner male portion 140 to form a passage 144 there between for receiving the female coupling member 130. At least one, in this case three, valve actuating portions 146 (two being shown in FIG. 7) are positioned in the passage 144 to abut the female coupling member 130 and to displace the valve member during the travel of the female coupling member 130 along the passage 144. In this case, each valve actuating portion 146 is integrally formed with the valve member 134.

Each valve actuating portion 146 includes a pair of abutment elements 150, 152 which are spaced from one another along the passage 144 to receive the female coupling member 130 there between and to travel with the female coupling member along the passage 144. The abutment element 152 has a bevelled outer surface 152a for reasons to be described. Each actuating portion 146 is longitudinally oriented relative to the passage 144 and the abutment elements 150, 152 are positioned along the actuating portion 146.

Each valve actuating portion 146 includes a locking flange 154 and the valve assembly includes a locking seat 156 to receive the locking flange 154 when the valve member 134 is in the closed position. In this case, the valve actuating portion 146 has a distal end region and the locking flange 154 is located in the distal end region, while the locking seat 156 is formed in the outer sheath portion 142.

It will be seen in FIG. **10** that each valve actuating portion **146** is arranged to flex in order to displace the locking flange **154** out of the locking seat **156**.

Referring to FIG. 8, the valve member 134 includes a back plate 160 and the actuating portions 146 are equally spaced on the back plate 160. The back plate 160 has a central fluid channel 162 which is in fluid communication with the chamber 124 and the valve member 134 has a fluid channel 163 therein in fluid communication with the central fluid channel 162 and hence the chamber 124. In addition, the fluid channel 163 has a lateral portion 163*a* which establishes fluid communication between the fluid channel 163 and an inner fluid channel 140*a* in the inner male portion.

The device 120 is thus used as follows. The valve assembly is set with the valve member in its closed position, that is with the valve member 134 in its position against the valve seat 136 as shown in FIG. 8. The female coupling member 130 on the needle 132 is aligned with the passage

144 and brought toward the male coupling member 128. The bevelled leading surface 152a on the abutment member 152 aids to centre the female coupling member on the mouth of the passage 144. With the locking flange 154 in the locking seat 156, the female coupling member 130 is able to pass the lowermost edge of the abutment element 152 and continue into the passage 144 until the female coupling member makes contact with the abutment element 150 as seen in FIG. 9. As seen in FIG. 10, continued inward force on the female coupling member is transferred to the abutment element 150 causing the abutment portion 146 to move inwardly along the passage and thus to draw the locking flange 154 from this locked position in the locking seat 156, causing the abutment portion 146 to flex, until the locking flange 154 is removed from the locking seat 156. At this position, it can be seen that the valve member 134 has moved from the valve seat 136 to open the fluid channel 163 to the needle 132.

Referring to FIG. 11, as the female coupling member 130 ₂₀ is removed from the passage 144, it makes contact with the abutment element 152 and causes the abutment portion 146 to move outwardly along the passage 144 and thus cause the valve member 134 to move toward the valve seat 136. The locking flange 154 approaches, and finally enters, the lock-²⁵ ing seat 156 to coincide with the closure of the valve assembly.

Thus, the device **120** does not make use of a valve member which is biased to its closed position as with the earlier embodiment, but rather relies on the displacement of ³⁰ the female coupling member **130** to draw the valve assembly to its closed position when it is removed from the male coupling member **128**.

Another device is shown at **170** in FIGS. **13** to **15**, having ³⁵ a body **172** providing a chamber **174** therein to contain a fluid material. A valve assembly **176** is in fluid communication with the chamber **174** and has a male coupling member **178** for engaging a female coupling member **180**, again on a needle **181**, to form a fluid coupling between the ⁴⁰ medical dispensing device **170** and the needle **181**.

The valve assembly **176** is operable to control fluid flow through the male coupling member and more particularly to actuate or open the male coupling member **178** when operatively connected with the female coupling member **180** and, conversely, to close the male coupling member **178** when disconnected from the female coupling member **180**.

In this case, the male coupling member **178** includes a projection **182** which is fixed to the body **172**. A sheath portion **184** encircles the projection **182** and is also fixed to 50 the body **172**. The sheath portion **184** and is spaced from the projection **182** to form a passage **186** to receive the female coupling member **180**.

A valve member **190** is movable relative to the projection **182** and forms a fluid channel **192** there between and sealed 55 by an inner seal **193**. The projection **182** includes an inner passage **194** which has one end **194***a* open to the chamber **174** and another end **194***b* which is open to the fluid channel **192**.

Referring to FIGS. 14 and 15, the projection includes an 60 enlarged end portion 198 and the valve member 190 has an outer portion 200 arranged to engage the enlarged end portion 198 to close the fluid channel 192. In this case, the passage 186 ends at an inner wall 202 and the valve member 190 is movable relative to the inner wall 202 under the 65 action of a spring 203 which is positioned in the passage 186 between the valve member 190 and the inner wall 202 to

8

bias the outer end portion 200 of the valve member 190 toward an engaged position with the enlarged end portion 198.

As can be seen in FIG. **15**, the enlarged end portion **198** and the outer end portion **200** on the valve member **190** have mating bevelled surfaces **198***a* and **200***a* respectively.

The valve member 190 is operable to engage the female coupling member 180 and to travel with the female coupling member 180 along the passage 186. In this case, the female coupling member 180 has a leading segment 180*a* and the outer end portion 200 of the valve member 190 is dimensioned to fit within the leading segment 180*a*.

In contrast to the device 120 of FIG. 6, the device 170 has a valve member 190 which is biased to the closed position. As the female coupling member 180 passes over the projection 182, the leading segment 180a of the female coupling member 180 rides over the outer end portion 200 of the valve element 190. Continued inward displacement of the female coupling member 180 into the passage 186 thus causes the valve member to move relative to the projection 182 until the mating bevelled surfaces 198a, 202a separate to open the fluid channel 192 to the needle. The fluid coupling is thus fully operational when the female and male coupling members are tightly engaged. When the female coupling member 180 is removed from the male coupling member 178, the valve member 190 is returned to its closed position against the projection 198 under the biasing action of the spring 203, to close the male coupling member.

While the present invention has been described for what are presently considered the preferred embodiments, the invention is not so limited. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. The scope of the following claims is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.

The valve unit may be used with other medical fluid delivery devices, such as IV lines, catheters, infusion pumps and the like. The valve unit may also be used on syringes and other medical devices which do not employ the ubiquitous luer coupling arrangement.

The following is claimed:

1. A method of providing a medical connector, the method 45 comprising:

providing a housing including a proximal portion and a distal portion;

providing a female luer;

- providing a male luer projection being located at the distal portion of the housing; and
- providing a valve member being longitudinally movable between a closed position and an open position, the valve member comprising:

an internal fluid pathway,

- a proximal end being moveable between the open position and the closed position, the moveable proximal end comprising an open-ended proximal end surface,
- at least one distal opening, and
- a distal end portion being located in a distal direction from the at least one distal opening, the distal end portion being configured to obstruct fluid communication between the male luer projection and the internal fluid pathway when in the closed position,
- wherein the valve member when in the closed position is configured to inhibit fluid flow through the internal fluid pathway, wherein the valve member when in

45

the open position is configured to allow fluid flow through the internal fluid pathway,

- wherein at least a portion of the valve member is positioned within the male luer projection in the closed position.
- wherein at least a portion of the valve member is positioned outside of the male luer projection in both the open position and the closed position, and
- wherein the valve member is biased toward the closed 10 position.
- 2. The method of claim 1, wherein the open-ended proximal end surface is wider than a distal-most end tip of the valve member.

3. The method of claim **1**, wherein the valve member is 15formed of a single piece of material.

4. The method of claim 3, wherein the at least one distal opening of the valve member comprises two distal openings.

5. The method of claim 1, wherein the distal end portion of the valve member comprises a plug. 20

6. The method of claim 1 further comprising providing an actuating member being configured to actuate at least a portion of the valve member from the closed position to the open position.

extends along the housing from:

- (i) a first region of the medical connector that is configured to receive an end of a medical article, to
- (ii) a second region of the medical connector containing the male luer projection.

8. The medical connector of claim 1 further comprising providing a biasing member being configured to assert a restoring force on the valve member, the restoring force being configured to move the valve member longitudinally within the housing to the closed position, wherein the 35 biasing member contacts a proximal half of the valve member.

9. A method of providing a medical connector configured to receive a male end of a medical article, the method comprising:

- 40 providing a housing comprising a proximal region and a distal region being separate from the proximal region, the proximal region being joined with the distal region;
- providing a female luer end being configured to receive a male end of a medical article;

providing a male luer projection;

- providing a threaded shroud surrounding at least a portion of the male luer projection, the threaded shroud comprising one or more threads;
- providing a valve member being longitudinally movable 50 between a closed position and an open position, the valve member comprising:
 - an internal fluid pathway,
 - at least one opening being moveable with the valve member and comprising a distal end being located 55 distal from a proximal end of the one or more threads of the threaded shroud in the open position, and

- a distal end portion being located in a distal direction from the at least one opening, the distal end portion being configured to inhibit fluid communication between the male luer projection and the internal fluid pathway when in the closed position, the distal end portion comprising a distal-most end tip being positioned within the male luer projection in both the open position and the closed position, wherein a proximal-most end of the valve member is wider than the distal-most end tip,
- wherein the valve member when in the closed position is configured to inhibit fluid flow between the internal fluid pathway and the male luer projection, wherein the valve member when in the open position is configured to allow fluid flow between the internal fluid pathway and the male luer projection through the at least one opening, and
- wherein the valve member is biased toward the closed position; and
- positioning the valve member within the housing such that at least a portion of the valve member is located outside of the male luer projection when the valve member is in both the open position and the closed position.

7. The method of claim 1, wherein the valve member 25 the valve member is positioned within the male luer pro-10. The method of claim 9, wherein at least a portion of jection in the closed position.

> 11. The method of claim 9, wherein the proximal-most end of the valve member comprises a proximal-facing opening.

> 12. The method of claim 9, wherein the at least one opening of the valve member further comprises two distal openings.

> 13. The method of claim 9, wherein the valve member is formed of a single piece of material.

> 14. The method of claim 13, wherein the valve member extends along the housing from:

- (i) a first region of the medical connector that is configured to receive the male end of the medical article, to
- (ii) a second region of the medical connector containing the male luer projection.

15. The method of claim 9, wherein the distal-most end tip of the valve member comprises a plug.

16. The method of claim 9 further comprising providing an actuating member being configured to actuate at least a portion of the valve member from the closed position to the open position.

17. The medical connector of claim 9 further comprising providing a biasing member being configured to assert a restoring force on the valve member, the restoring force being configured to move the valve member longitudinally within the housing to the closed position, wherein the biasing member contacts a proximal half of the valve member.

18. The method of claim 9 further comprising providing the medical article.